apomorphine hydrochloride · Sumitomo Pharma Am · NDA 210875
Kynmobi
Earliest generic entry, as listed · earliest of 5 marketed strengths
19 Apr 2036
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10449146, US 10959943. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 12 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10449146 | use U-2825 · sets the listed date | 19 Apr 2036 |
| US 10959943 | use U-2825 · sets the listed date | 19 Apr 2036 |
| US 11419769 | drug product, use U-2825 | 16 Dec 2031 |
| US 8414922 | drug product, use U-2825 | 16 Dec 2031 |
| US 8846074 | drug product, use U-2825 | 16 Dec 2031 |
| US 10420763 | drug product, use U-2825 | 11 Jun 2030 |
| US 9044475 | drug product | 11 Jun 2030 |
| US 9283219 | drug product, use U-2825 | 11 Jun 2030 |
| US 9326981 | use U-2825 | 11 Jun 2030 |
| US 9669019 | drug product, use U-2825 | 11 Jun 2030 |
| US 9669021 | use U-2825 | 11 Jun 2030 |
| US 10821074 | drug product | 7 Aug 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210875 · 001 · RLD · discontinued | film, sublingual | 10MG | 19 Apr 2036 |
| 210875 · 002 · RLD · discontinued | film, sublingual | 15MG | 19 Apr 2036 |
| 210875 · 003 · RLD · discontinued | film, sublingual | 20MG | 19 Apr 2036 |
| 210875 · 004 · RLD · discontinued | film, sublingual | 25MG | 19 Apr 2036 |
| 210875 · 005 · RLD · discontinued | film, sublingual | 30MG | 19 Apr 2036 |